

The Endocannabinoid System: An Osteopathic Perspective

John M. McPartland, DO

The present review provides an update on endocannabinoid basic science and clinical studies and proposes a new model to describe reciprocal interactions between somatic dysfunction and the endocannabinoid system. The endocannabinoid system consists of cannabinoid receptors, endogenous ligands, and ligand-metabolizing enzymes. The system exemplifies the osteopathic principle that the body possesses self-regulatory mechanisms that are self-healing in nature. Enhancing endocannabinoid activity has broad therapeutic potential, including the treatment of patients with somatic dysfunction, chronic pain, and neurodegenerative diseases as well as inflammatory conditions, bowel dysfunctions, and psychological disorders. Blockade of the endocannabinoid system with drugs such as rimonabant and taranabant may oppose self-healing mechanisms and elicit adverse effects. Osteopathic physicians wield several tools that can augment endocannabinoid activity, including lifestyle modifications, pharmaceutical approaches, and osteopathic manipulative treatment.

J Am Osteopath Assoc. 2008;108:586-600

The endocannabinoid system was discovered long after the endorphin system, which was indirectly detected in 1801 when morphine sulfate was isolated from opium. Morphine's mechanism of action remained a mystery until the opioid μ receptor was identified. That discovery begged the question: Why do humans express a receptor for an opium poppy (*Papavera somniferum*) plant compound? Scientists quickly identified endorphins and enkephalins, which are endoge-

nous compounds mimicked by the plant compound.¹

In 1897, Andrew Taylor Still, MD, DO,² the founder of osteopathic medicine, famously stated, "Man should study and use the drugs compounded in his own body." Still hypothesized that osteopathic manipulative treatment (OMT) stimulated endogenous compounds that promoted homeostasis and healing. Not long after the discovery of endogenous opioids in 1975, *JAOA—The Journal of the American Osteopathic Association* published a supplement dedicated to endorphins and enkephalins.³ However, the initial enthusiasm dampened after seven subsequent studies^{4,5} showed no effects of OMT or chiropractic manipulation on serum levels of these compounds.

Since then, research—particularly osteopathic medical research—has redirected its attention from the endorphin system to the endocannabinoid system.⁴⁻¹⁰ A search on the National Library of Medicine's PubMed database of *endorphin* in the 1992 literature, the year endocannabinoids were discovered, returns 596 citations, whereas *endocannabinoid* yields only two citations. In a search limited to 2007, *endorphin* produces 122 citations, whereas *endocannabinoid* generates 480 citations.

The primary purpose of the current article is to review the expanding endocannabinoid literature beginning with exogenous compounds—*Cannabis* and plant cannabinoids—and then shift to the endogenous system, highlighting embryology and development, neuroprotection, autonomic and immunity, inflammation, apoptosis, hunger and feeding, and nociception and pain.

Because the literature is so voluminous—more than 10,000 cannabinoid citations in PubMed—the present article is not a systematic review. Review articles were considered the preferred source and are referenced throughout to enable continued education.

In addition, the present review seeks to draw parallels between the endocannabinoid system and the principles of osteopathic medicine.¹¹ The endocannabinoid system is a homeostatic mechanism that exemplifies the key osteopathic concepts of mind-body unity¹¹ on a molecular level. A new neuroimmunologic model describes reciprocal interactions between the endocannabinoid system and the osteopathic concept of somatic dysfunction. Finally, the current review will describe how osteopathic physicians may enhance endocannabinoid function in their patients.

From the Department of Osteopathic Manipulative Medicine at Michigan State University College of Osteopathic Medicine in East Lansing.

This work began under the aegis of a Unitec AssocProf research grant (School of Osteopathy, Unitec New Zealand). A lecture based on this manuscript was presented at the 2007 meeting of the American Academy of Osteopathy in Birmingham, Ala, on March 27, 2006. The author serves as a scientific advisor for the Cannabinoid Research Institute, a research division of GW Pharmaceuticals.

Address correspondence to John M. McPartland, DO, 53 Washington St Ext, Middlebury, VT 05753-1288.

E-mail: mcpruitt@verizon.net

Submitted June 6, 2007; final revision received February 20, 2008; accepted March 3, 2008.

Exogenous Cannabinoids

The plant *Cannabis sativa*, the source of cannabis (ie, marijuana, hashish), is native to central Asia. Several indigenous “traditional medicine” systems (eg, Ayurvedic medicine, Tibetan medicine, traditional Chinese medicine) evolved and make use of this substance.¹²

In the 1830s, a physician serving the British Crown in India conducted a series of laboratory experiments, including animal studies and clinical trials, to determine the safety and efficacy of cannabis. He subsequently introduced cannabis to England and was knighted by Queen Victoria.¹³

Cannabis entered *The Dispensatory of the United States of America* in 1854.¹⁴ Although cannabis met a variety of applications, its primary use was for the alleviation of pain and spasticity. In fact, Sir William Osler considered cannabis the “most satisfactory remedy” for migraine.¹⁵

In the late 19th and early 20th centuries, cannabis was manufactured by a number of pharmaceutical companies in the United States and was dispensed as an orally administered fluid extract. When coupled with variable product potency, unreliable sources of supply, poor storage stability, and evidence that the liquid form was erratically absorbed by the gut, fluid extracts soon fell out of favor.¹³ Its decline in popularity was further hastened by new and inexpensive synthetic medicines such as aspirin. Finally, after growing concern of “reefer madness,” cannabis was prohibited in 1937 despite vigorous opposition by the American Medical Association.¹⁶ In fact, many leaders in the allopathic medical profession continue to support the medicinal use of cannabis.¹⁷

Whereas morphine forms a water-soluble salt easily isolated from *Papaver somniferum*, the active ingredients in cannabis are lipophilic and resist crystallization. In 1964, after foiling scientists for 150 years, Raphael Mechoulam isolated Δ^9 -tetrahydrocannabinol (THC) and cannabidiol.¹² More than 70 separate 21-carbon terpenophenols unique to cannabis, collectively called the cannabinoids, have been identified by Mechoulam,¹² Pertwee,¹⁸ and others.

Animal studies of THC began immediately after its discovery. By 1975, the first phase 3 clinical trials were published.^{12,18} Dronabinol, a synthetic THC, was approved as a schedule II drug in 1986 and was moved to schedule III in 1999.¹⁷ Its indications include nausea and vomiting associated with cancer chemotherapy as well as appetite and weight loss in patients with AIDS.¹⁹ Nabilone, a THC analog with the same indications, was approved by the US Food and Drug Administration in 1985 but was not marketed in the United States until 2006.²⁰

Receptors and Signal Transduction

Discovery of the μ -receptor launched a search for cannabinoid receptors. However, the search was stymied by THC because of its nonspecific (ie, indiscriminate) binding.

In 1988, Howlett et al developed synthetic, water-soluble THC analogs showing that a radiolabelled cannabinoid

receptor agonist ($[^3\text{H}]\text{CP55,940}$) bound specifically to a receptor located in neuron cell membranes.²¹ Two years later, Matsuda and Bonner cloned the gene for the receptor, which translated into a chain of 472 amino acids that weave back and forth across the cell membrane seven times.²¹ This weaving structure is the same as those of G protein-coupled receptors (GPCRs), which are named for their G (guanine nucleotide binding) proteins and function as intracellular “molecular switches.” Well-known GPCRs include opioid, dopamine, serotonin, and β -adrenergic receptors.

Each GPCR possesses a unique binding pocket with an affinity for specific ligands, like a lock-and-key mechanism. When a ligand docks in the binding pocket, it may initiate any of the following changes, depending on the agonist:

- **Full agonists**—These agonists, such as morphine and β -endorphin, maximally activate receptors.
- **Partial agonists**—These agonists submaximally activate receptors, often less than an endogenous ligand. For example, the β -blocker pindolol occupies the norepinephrine binding site but exerts much less activity.
- **Neutral antagonists**—Agonists in this category, such as naloxone hydrochloride and alprenolol, dock at receptors but do not activate them.
- **Inverse agonists**—These agonists, such as metoprolol succinate, metoprolol tartrate, prazosin hydrochloride, cimetidine and haloperidol deactivate receptors by suppressing their spontaneous activity.

A ligand docking in a GPCR distorts the shape of the GPCR's transmembrane weave of amino acids (a “conformational change”), thereby altering the intracellular side of the receptor and its interface with the G protein. If the ligand is an agonist, the G protein decouples from the receptor and couples to an ion channel (eg, K^+ , Ca^{2+}) or enzymes (eg, adenylyl cyclase), causing a “signal cascade” that governs cell behavior.²¹

The cannabinoid receptor can activate different G protein subtypes. For example, subtype G_o couples to ion channels, G_i inhibits adenylyl cyclase, and G_s stimulates adenylyl cyclase.²¹ The deciding factor is the agonist because various agonists preferentially direct the receptor toward the different G protein subtypes.²¹ This “agonist trafficking” may explain why different strains of cannabis produce different psychoactive effects.²² Agonist trafficking alters the traditional lock-and-key metaphor. In this setting, an assortment of keys unlock the same lock, but the door opens into different rooms.

Cannabinoid receptors are the most common GPCRs in the brain, but they are unevenly distributed. High densities are found in the basal ganglia, which is composed of the globus pallidus, substantia nigra, and striatum (comprising the caudate nucleus and putamen); hippocampus; cerebral cortex; cerebellum; and amygdaloid nucleus.²³ Receptor distribution accounts for the well-known effects of cannabis on short-term memory, cognition, mood and emotion, motor function, and

nociception. Unlike μ -receptors, cannabinoid receptors are virtually absent in brainstem cardiorespiratory centers, which probably account for the lack of lethal effects from cannabis overdose.²³

Cannabinoid receptors are downregulated and desensitized when exposed to high doses of THC. This effect results in “drug tolerance,” which occurs at varying rates and magnitudes in different brain regions. For example, it occurs faster and greater in the hippocampus, which regulates memory, compared with the basal ganglia, which mediates euphoric effect.²⁴ This difference may explain why memory loss decreases among frequent cannabis users, but its euphoric effects remain.²⁵

Curiously, cannabinoid receptors may activate G proteins in the absence of THC or endogenous cannabinoid compounds.²¹ This “constitutive activity” is difficult to separate from “endogenous tone” experimentally, where tonic release of endocannabinoids activates the receptors. Constitutive activity has also been measured in other GPCRs, such as the angiotensin receptor, which is stretched into an active conformation by hydrostatic pressure in blood vessels.²⁶

A second cannabinoid receptor, CB₂, was discovered in 1993. While the first receptor, CB₁, is principally located in the nervous system, CB₂ is primarily associated with cells governing immune function: leukocytes, splenocytes, and microglia.²¹ The genes for CB₁ and CB₂ are paralogs (ie, genes separated by a gene-duplication event), with orthologs (ie, genes separated by speciation events) in all vertebrate species investigated to date.²⁷

In fact, orthologs of cannabinoid receptors have been identified in primitive organisms, such as nematodes and sea squirts, which suggests cannabinoid receptors evolved 600 million years ago.²⁸ Therefore, from an evolutionary perspective, human CB₁ is under strong purifying selection, whereas CB₂ is under reduced functional restraint. In fact, the mutation rate of CB₂ is four times higher than CB₁.²⁹

Endogenous Cannabinoids

Humans likely did not evolve receptors for a *Cannabis* compound. Indeed, the cannabinoid receptor evolved long before cannabis, which is not more than 34 million years old.²² The first endogenous cannabinoid, anandamide (AEA), was discovered by Mechoulam in 1992—nearly 30 years after he discovered THC. The discovery of 2-arachidonoylglycerol (2-AG) occurred shortly thereafter.

Both the AEA and 2-AG endocannabinoids are metabolites of arachidonic acid. They do not resemble THC but nonetheless fit the CB₁ and CB₂ binding pockets. Therefore, the effects of THC, AEA, and 2-AG substantially overlap, activating the same receptors.³⁰ However, THC is a partial agonist and may block 2-AG’s full agonist activity in some situations.^{31–33}

Unlike classic neurotransmitters, AEA and 2-AG are not stored in vesicles. Instead, they are synthesized and released

“on demand” from precursor phospholipids within the cell membrane. The AEA endocannabinoid is cleaved from its precursor phospholipid by the enzymes N-acyl phosphatidylethanolamine phospholipase D and alpha-beta hydrolyase 4, while 2-AG is cleaved from its precursor diacylglycerol (DAG) by two DAG lipase enzymes, DAGL α and DAGL β .

After release into the synapse, AEA and 2-AG activate CB₁. Thereafter, several other catalytic enzymes break down AEA and 2-AG.^{18,34} Several agents that block catalytic enzymes—specifically fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)—have been described, which prolong AEA and 2-AG synaptic activity, analogous to a serotonin uptake inhibitor. Pharmacologists are searching for inhibitors of the other endocannabinoid enzymes as well.¹⁸ Although few endogenous inverse agonists are known for any receptors, one inverse agonist called *hemopressin* was discovered for CB₁ and has exhibited surprising analgesic properties.³⁵

Within the central nervous system, the endocannabinoid system acts as a negative feedback mechanism to dampen synaptic release of classic neurotransmitters. A simplified example is presented in *Figure 1*. Persistent activation of a nerve—in this case, a sensory C-fiber nociceptor—causes excessive release of glutamate from its central terminal, which synapses in the dorsal horn. Excessive glutamate causes an upregulation of glutamate receptors in the postsynaptic cell (in this case, a wide dynamic range neuron). Persistent nociception and upregulated glutamate receptors lead to a form of neural plasticity known as *central sensitization*.^{36,37} Neural plasticity is characterized by the sprouting and pruning of synapses, changes in dendritic spine density, and changes in neurotransmitter pathways. It gives rise to all types of adaptive learning, including the subcortical events leading to a facilitated spinal segment³⁷ as well as the conscious act of gaining a new skill or the unconscious acquisition of a new emotional response.³⁸

Central sensitization elicits a homeostatic response by the endocannabinoid system: upregulated glutamate receptors in the post-synaptic cell lead to an influx of Ca²⁺ (*Figure 1A*), which causes DAGL α enzymes in the post-synaptic cell to synthesize 2-AG (*Figure 1B*). The 2-AG endocannabinoid moves retrograde (ie, opposite the direction of glutamate) across the synapse to CB₁, located on the presynaptic neuron. The activated CB₁ closes presynaptic Ca²⁺ channels, which then halts glutamate vesicle release.³¹ This “retrograde signaling” mechanism is termed *depolarization-induced suppression of excitation* (DSE) and enables the postsynaptic cell to control its own incoming synaptic traffic.

Alternatively, if endocannabinoids transiently attenuate the release of an inhibitory neurotransmitter such as γ -aminobutyric acid, the mechanism is termed *depolarization-induced suppression of inhibition* (DSI).³¹ As a ubiquitous phenomenon, DSI modulates neurotransmission in the hippocampus, cerebellum, basal ganglia, cerebral cortex, and amygdaloid nucleus.³¹




Figure 1. Retrograde transmission at the dorsal horn. Nociceptor action potentials open calcium (Ca^{2+}) channels in the presynaptic axon terminal, which cause vesicles of glutamate to release into the synaptic cleft. (A) Excessive glutamate release causes upregulation of glutamate receptors in the postsynaptic cell, which open Ca^{2+} channels. (B) Postsynaptic calcium influx stimulates diacylglycerol lipase enzymes to synthesize 2-AG, which diffuses across the synapse to the presynaptic cell and activates CB_1 , which closes presynaptic Ca^{2+} channels, arresting the release of glutamate vesicles. **Abbreviations:** AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; eCBS, endocannabinoid system; mGLU, metabotropic glutamate receptor; NMDA, N-methyl-D-aspartic acid receptor. Reprinted with permission from the Journal of Bodywork and Movement Therapies.¹⁰ Copyright Elsevier, 2008.

Although DSE is less common and the data suggest CB_1 occurs both pre- and postsynaptically in the dorsal horn,³⁶ evidence indicates that DSE dampens nociception at the spinal level.³⁹ The endocannabinoid system also controls other forms of neural plasticity such as long-term depression, which is caused by a sustained decrease in glutamate release from presynaptic cells.⁴⁰

Embryology and Development

For endocannabinoid receptors to survive 600 million years, they must serve evolutionarily important functions. The CB_1 receptors have been detected in mouse embryos as early as the second day of gestation.⁴¹ Blastocysts express CB_1 , CB_2 , and FAAH, and blastocyst implantation into the endometrium requires suitable levels of AEA.⁴¹ In fact, the endocannabinoid system organizes a broad array of developmental processes in the embryonic brain. Proliferation and differentiation of neural stem cells are shaped by extracellular cues provided by endocannabinoids.⁴² Indeed, once stem cells commit to neurogenesis, endocannabinoids regulate neuronal migra-

tion and synaptogenesis. Lastly, axon guidance is shaped by axon growth cones, and endocannabinoids are part of the molecular "soup" that guides growth cones to their destinations.⁴³

Adult neurogenesis is regulated by many of these "embryonic" mechanisms and primarily arises in neural stem cells within the subependymal layer lining the cerebral ventricles and the dentate gyrus of the hippocampus. Neural stem cells in both of these brain regions express CB_1 ,⁴⁴ and neurogenesis by these cells is driven by the endocannabinoid system.⁴⁵

Considering the prominence of the endocannabinoid system in embryogenesis, its equal importance in adult neurogenesis brings to mind a quote by James Jealous, DO:

The formative and regenerative forces that organize embryological development are present throughout our life span [...]. In other words, the forces of *embryogenesis* become the forces of *healing* after birth.⁴⁶

Neuroprotection

The anti-inflammatory, antioxidant, and antispasmodic properties of THC and cannabidiol in cannabis reduce the symptoms and slow the progression of multiple sclerosis. These properties also benefit patients with Huntington disease and amyotrophic lateral sclerosis.⁴⁷ Dampening of glutamate excitotoxicity prevents epileptic attacks and limits infarct size post-stroke. Both AEA and 2-AG thwart Alzheimer disease by blocking microglial activation and β -amyloid plaque formation. They also prevent Parkinson disease symptoms by rebalancing neural activity in the striatum.⁴⁷

Although controversial, the endocannabinoid system has been associated with psychotic disorders. Individuals with schizophrenia have elevated levels of AEA in their cerebrospinal fluid, but the elevated levels are *negatively* correlated with psychotic symptoms.⁴⁸ This association suggests that abnormal activation of postsynaptic D₂ receptors trigger the release of AEA and retrograde signaling via CB₁, thus homeostatically attenuating dopamine release. High doses of THC may therefore provoke psychiatric illness in susceptible individuals by desensitizing CB₁ receptors and diminishing retrograde signaling.⁴⁸ Alternatively, cannabidiol, which is not psychoactive, shows promise as an antipsychotic agent.⁴⁹

Autonomic Function and Immunity

Endocannabinoids and THC affect autonomic outflow through the peripheral and central nervous systems. The endocannabinoid system reduces elevated parasympathetic activity, providing the antiemetic effects of cannabinoids.¹⁸

In rodent studies, activation of myocardial CB₁ caused vagally mediated biphasic effects in heart rate and cardiac contractility, while activation of CB₁ in vascular tissues leads to vasodilation.⁵⁰

Cannabinoids provide antihypertensive benefits in humans and a protective role in myocardial ischemia has been suggested in rodent studies.⁵⁰ However, human *in vitro* studies have implicated the autonomic effects of THC and endocannabinoids in hypotension associated with hemorrhagic and endotoxic shock. The autonomic effects have also been described in human clinical studies on advanced liver cirrhosis.⁵⁰

Sympathetic nerve terminals contain CB₁, and activation of these receptors has been shown to inhibit norepinephrine release and dampen sympathetically mediated pain.⁵⁰ The endocannabinoid system modulates the sympathetically driven hypothalamic-pituitary-adrenocortical (HPA) axis as well as the hypothalamic-locus coeruleus-norepinephrine (HLN) axis. Psychologic stress induces the secretion of corticotropin-releasing hormone, which activates the HPA and HLN axes and results in corticosteroid and norepinephrine release, respectively. The endocannabinoid system blocks HPA and HLN axis activation, though doses of THC may cause the reverse response and increase corticotropin-releasing hormone and anxiety.⁵⁰

In addition, HPA axis activation hinders the immune response. Cannabinoids are immunomodulators—not simply immunosuppressors, as they were characterized in the 1970s.^{51,52} Cannabinoids suppress production of T-helper 1 (TH1) cytokines such as interleukin (IL) 2, immune interferon (INF- γ), and tumor necrosis factor α (TNF- α). On the other hand, cannabinoids increase secretion of TH2 cytokines (eg, IL-4, IL-5, IL-10). Other subsets of lymphocytes, including B cells (eg, MZ, B1a) and natural killer cells, require endocannabinoids and CB₂ to function properly.^{51,52} *Cannabis*, *Echinacea*, and other plant products that stimulate resistance to infection and fatigue have been described as “adaptogens”—natural products that work “osteopathically” by enhancing health rather than fighting disease.⁵³ The alkylamides in *Echinacea* potently agonize CB₂ and stimulate phagocytosis.⁵⁴ The lack of psychoactivity caused by *Echinacea* can be attributed to the relative lack of CB₂ in the brain.

Inflammation and Connective Tissues

More than 4000 years ago, the Chinese physician Shen Nung recommended cannabis for rheumatic pains.¹² More recently, patients with myofascial pain and arthritis are among those who most often use cannabis medicinally.¹³ Activation of CB₂ suppresses proinflammatory cytokines such as IL-1 β and TNF- α while increasing anti-inflammatory cytokines such as IL-4 and IL-10.^{51,52} Although THC has well-known anti-inflammatory properties, cannabidiol also provides clinical improvement in arthritis via a cannabinoid receptor-independent mechanism.¹⁸ Many connective tissue-related cells express CB₁, CB₂, and endocannabinoid-metabolizing enzymes such as fibroblasts, myofibroblasts, chondrocytes, and synoviocytes.¹⁰

The endocannabinoid system alters fibroblast “focal adhesions,” by which fibroblasts link the extracellular collagen matrix to their intracellular cytoskeleton—the mechanism of fascial remodeling. Cannabinoids prevent cartilage destruction such as proteoglycan degradation and collagen breakdown by inhibiting chondrocyte expression of cytokines and metalloproteinase enzymes.¹⁰ In addition, the tonic release of endocannabinoids is upregulated in rats that have experimentally induced osteoarthritis, thereby providing endogenous pain relief.⁵⁵

The endocannabinoid system has been shown to attenuate allergic contact dermatitis in rodent studies—THC decreases allergic inflammation whereas CB₁-blocking agents exacerbate the condition.⁵⁶ The endocannabinoid system likewise protects against Crohn disease—a TH1-mediated inflammatory bowel condition—and also perhaps ulcerative colitis.^{6,51,52} The endocannabinoid system dampens the inflammatory component of atherosclerosis in animal studies via CB₂ receptors expressed by macrophages within atherosclerotic plaques.¹⁸ Lastly, the endocannabinoid system is essential for the maintenance of normal bone mass: CB₂ agonists enhance osteoblast activity and inhibit osteoclast activity, therefore offering a potential treatment option for osteoporosis.⁵⁷

Apoptosis

With the exception of cannabis smoke, cannabinoids are anti-carcinogenic. They have been found to induce apoptosis in cancer cells via a CB₁-mediated ceramide-caspase pathway, thereby inhibiting tumor growth in breast, prostate, and lung carcinomas as well as gliomas, melanomas, lymphomas, and other cancers.⁵⁸ In normal, nontransformed cells, endocannabinoids actually promote cell survival via the extracellular signal-regulated kinase (ERK) pathway.⁵⁸

Reducing apoptosis in normal cells is one mechanism by which cannabinoids act as neuroprotectants.⁴⁷ Cannabinoids also suppress tumor angiogenesis.⁵⁸ However, one contrary study⁵⁹ reported that the CB₂ gene serves as a retrovirus insertion site (ie, a proto-oncogene) involved in leukemic transformation.

Nociception and Pain

Research on the effects of endocannabinoids on nociception has focused on the following four areas:

- peripheral terminals of nociceptors
- the dorsal horn
- the descending pain inhibitory pathway
- supratentorial sites

Peripheral terminals of C-fiber nociceptors contain receptors for “activators” and “sensitizers” (Figure 2). Activators trigger an action potential in the nerve while sensitizers decrease the nerve’s activation threshold, so it fires with less activation.

Activators and sensitizers are released from damaged tissue (eg, K⁺ and H⁺ ions, bradykinins, adenosine triphos-

phates), leukocytes (eg, histamines, prostaglandins, leukotrienes, proinflammatory cytokines), leukocyte-activated platelets (eg, 5-hydroxytryptamine), neighboring autonomic nerves (eg, norepinephrine, and the nociceptor itself (ie, substance P and calcitonin gene-related peptide)). Activators and sensitizers cause peripheral sensitization, including hyperalgesia and allodynia. Peripheral sensitization elicits a homeostatic response by the endocannabinoid system: CB₁ signaling decreases the release of activators and sensitizers around the site of tissue injury and opens K⁺ channels in the nociceptor cell membrane, so the nerve becomes hyperpolarized and less likely to fire.³⁶

In addition, CB₂ signaling decreases the release of activators and sensitizers from neighboring mast cells and macrophages (Figure 2).³⁶ Functioning of the endocannabinoid system at the peripheral terminal of the nociceptor provides the “first line of defense against pain.”⁶⁰

In the dorsal horn, the nociceptor synapses with a nociceptive-specific neuron or a wide dynamic range neuron. Normally, the nociceptor action potential arrives at the dorsal horn and releases glutamate and substance P into the synaptic cleft. These neurotransmitters bind to their respective receptors in the postsynaptic cell. Cell activation initiates another action potential that ascends to the brain. Abnormal persistent release of glutamate upregulates glutamate receptors in the postsynaptic cell, as illustrated in Figure 1. As previously described, this causes an influx of Ca²⁺ in the post-synaptic cell and leads to central sensitization, “wind-up,” or “dorsal horn memory.”³⁷

However, Ca²⁺ influx elicits endocannabinoid synthesis, followed by retrograde signaling, and quickly shuts down presynaptic glutamate release. In other words, the endocannabinoid system induces “dorsal horn memory loss” and




Figure 2. Polymodal C-fiber nociceptor with an enlarged view of its distal terminal, its cell body in the dorsal root ganglion, and central terminal in the dorsal horn. Several nociceptor activators (Roman) and sensitizers (italic) are illustrated with their corresponding receptors named by gene symbols. The distal terminal also expresses CB₁ and two ion channels (G protein-coupled Kir3 [GIRK] and sensory neuron sodium [Na_v 1.8]) regulated by the receptor. A sympathetic postganglionic neuron and lymphocyte expressing CB₂ are located nearby the distal terminal. **Abbreviations:** 5-HT, 5-hydroxytryptamine; ATP, adenosine triphosphate; NGF, nerve growth factor. Reprinted with permission from the Journal of Bodywork and Movement Therapies.¹⁰ Copyright Elsevier, 2008.

short-circuits central sensitization.³⁶

The “descending pain inhibitory pathway” in rodents and humans is activated by the perception of pain in the brain. The pathway descends through the periaqueductal gray (PAG) and periventricular gray in the midbrain to the nucleus raphe magnus in the rostroventral medulla, and down to the dorsal horn of the spinal cord.

Endorphins, endocannabinoids, serotonin, norepinephrine, and adenosine play important roles in this pathway. Endocannabinoids and CB₁ are found in high concentration in the PAG, periventricular gray, nucleus raphe magnus, and dorsal horn, where they suppress GABA-releasing interneurons that inhibit neurons in the descending pathway.³⁶

The coordinated release of endocannabinoids in this pathway mediates a rodent model of “stress-induced analgesia,”⁶¹ the well-known phenomenon in which individuals are less responsive to pain immediately after encountering an environmental stressor (eg, soldiers wounded in action may not feel pain during the battle). The endocannabinoid and endorphin systems colocalize within the descending pathway. This process indicates how endocannabinoids and THC can work synergistically with morphine to provide a “morphine-sparing effect.”³⁶ A rodent study⁶² also showed that activated CB₂ receptors stimulated the release of β-endorphins.

Nociceptive input into supratentorial sites, such as the cortex and limbic structures, registers as pain and suffering. Rodent and human studies show that endocannabinoids squelch amygdala-based aversive memories and fear conditioning.^{63,64} Painful memories, fear, and anxiety are factors that turn chronic pain into chronic suffering. Thus, the endocannabinoid system may benefit hospice patients and those unable to extinguish painful memory (eg, patients with post-traumatic stress disorder).⁶³

Defacilitation of the amygdala also rebalances the autonomic system and boosts “off-cell” activity in descending pain inhibitory pathways in rodents.⁶⁵ Cannabis imparts supratentorial “cannabimimetic” effects, such as anxiolysis, alleviation of suffering, increased sense of well-being, and even euphoria.⁶⁶ Although AEA and 2-AG have not been injected into human subjects, the augmentation of endocannabinoids using OMT has caused them to feel “high, happy, light-headed, and hungry.”⁵ Similarly, exercise-induced “runner’s high” correlated with augmented levels of serum AEA.⁶⁷

Hunger and Feeding

Marijuana-enhanced hunger and feeding (“the munchies”) is a behavior that teleologically begins in utero. Blastocyst implantation has been characterized as organisms’ first suckling function—the blastocyst actively orients itself so it implants “head first” into the endometrium, followed by its uptake of nutrients⁶⁸—and blastocyst implantation requires a functional endocannabinoid system.⁴¹ At the other end of gestation, newborn mice given rimonabant, a drug that blocks CB₁, will stop suckling and die.⁶⁹

The endocannabinoid system modulates cell metabolism via ghrelin, leptin, orexin, and adiponectin signaling pathways.⁷⁰ Obesity leads to excessive production of endocannabinoids by adipocytes, which drives CB₁ into a feed-forward dysfunction, contributing to metabolic syndrome.⁷⁰

A pharmaceutical corporation recently sought approval of rimonabant for the treatment of obesity. However, the US Food and Drug Administration rejected it, in part, because 26% of subjects who took rimonabant in clinical studies reported depressed mood, irritability, agitation, anxiety, insomnia, headache, or other adverse psychiatric effects.⁷¹ Given the many beneficial roles of the endocannabinoid system, it should be no surprise that rimonabant unmasked previously silent multiple sclerosis and seizure disorders and doubled the risk for suicidality.⁷¹

Mood disorders call into question the external validity (or generalizability) of rimonabant clinical trials because patients with depression were excluded from the studies, yet psychiatric illness was the leading reason subjects dropped out of the studies.⁷² In standard clinical practice, approximately 50% of patients seeking treatment for obesity also suffer from depression.⁷³

Complete blockade of CB₁ might approximate the phenotype expressed by genetically engineered “CB₁ knockout mice.” Mice lacking CB₁ have increased morbidity, premature mortality, age-related neuron loss, and show greater, epilepsy, and anhedonia. They also exhibit aggressive, anxiogenic-like, and depressive-like behavior, as well as a fear of newness.^{74,75}

Compared with mice, humans have a higher “endocannabinoid tone.”⁷⁶ Rimonabant blocks endocannabinoid tone at CB₁ and spontaneous CB₁ constitutional activity because it works as a full inverse agonist. As suggested in one study,²² sustaining a baseline endocannabinoid “hedonic tone” in the mesolimbic system may enable humans to maintain personal optimism and productivity in the face of chronic societal stress and an ultimately unrewarding consumer culture. Thus, systemic CB₁ blockade may not help a psychologically stressed obese patient who does not exercise and whose diet is high in refined sugars, white flour, and trans fatty acids, and lacks fiber, vegetables, and omega-3 fatty acids.

Rimonabant is currently approved in Europe, and similar drugs, including taranabant, surinabant, CP-945598, and SLV-319, are in development (see www.clinicaltrials.gov). Although the risk-benefit profile of systemic CB₁ full inverse agonists may prohibit their use for chronic conditions such as obesity and drug or alcohol dependence, they could serve in the treatment of acute endocannabinoid dysregulation, such as hepatic cirrhosis, hemorrhagic or endotoxic shock, cardiac reperfusion injury, and doxorubicin-induced cardiotoxicity.⁵⁰

The use of a CB₁ partial agonist may prevent adverse psychiatric effects while simultaneously acting as a partial antagonist by blocking the binding of endocannabinoids at CB₁. Partial agonists serve best as partial antagonists when

levels of endogenous agonists are elevated—the exact scenario seen with endocannabinoids and obesity.⁷⁰ Partial agonists are currently used in cardiology (eg, pindolol) and psychiatry (eg, aripiprazole, buspirone hydrochloride), with fewer adverse effects than antagonists or inverse agonists and without compromising clinical efficacy. In animal studies, two partial agonists have been shown to reverse obesity: the 5-HT₆ ligand E-6837⁷⁷ and a Chinese herbal formula with an “undisclosed herb” that acts as CB₁.⁷⁸

Partial agonists often act as pleiotropic drugs, also known as “selectively nonselective drugs.” These “magic shotguns” interact with several molecular targets and provide superior therapeutic effects and adverse effect profiles compared with the action of a selective, single “magic bullet.”^{79,80}

Biological Oscillators

The endocannabinoid system alters every biological oscillator or pacemaker cell investigated to date, beginning with somite formation in the embryo. The segmentation clock converts oscillating *Hox* genes into spatial somite patterns.⁸¹ Fibroblast growth factor regulates the *Hox* clock,⁸¹ and evidence suggests that it uses endocannabinoid signaling.^{30,82,83} Many endocannabinoid-altered oscillators change the rhythms of tissue movement, such as:

- **Cardiac pulse rate and contractility**—Endocannabinoids have been reported to cause dose-related biphasic effects in rodents and humans.⁵⁰
- **Thoracic respiration**—Endocannabinoids cause little change in thoracic respiration, though intravenous injection of high-dose synthetic CB₁ agonists in urethane-anaesthetized rats decreased the respiration rate.⁵⁰
- **Gastrointestinal motility and peristalsis**—Slowing of rate and rhythm and gastrointestinal secretions in rodents and humans.⁵⁰

Human consciousness represents the rhythmic entrainment of synchronously firing neurons.⁸⁴ In five regions of the human brain,²³ such neurons are particularly enriched with CB₁:

- The **hippocampus** is a source of theta and gamma band oscillations and is the neural substrate responsible for declarative memory.⁸⁵
- **Striatal tissues** contribute to the “beat frequency” model of time perception.⁸⁶
- The **cerebellum** plays a role in rhythm production and self-paced-behaviors, and cannabis accelerates the cerebellar clock.⁸⁷
- The **suprachiasmatic nucleus** is responsible for controlling circadian rhythms.^{88,89}
- The **pineal gland** produces melatonin and 2-AG in a circadian rhythm driven by the suprachiasmatic nucleus and regulated in part by CB₂ in animal studies.⁹⁰

Role of Osteopathic Medicine

Osteopathic principles and practice (OPP) were established by Still in the late 19th century. The endocannabinoid system may reflect OPP on a molecular level. Leaders in the osteopathic medical profession proposed four tenets of OPP,¹¹ which are presented below, accompanied by a description of their relationship to the endocannabinoid system.

1. **A person is the product of dynamic interaction between body, mind, and spirit**—This holistic principle is exemplified by cannabinoid receptors, which span the field of psychoneuroimmunology. Taken together, CB₁, CB₂, and their endocannabinoid ligands represent a microcosm of mind-body medicine.
2. **An inherent property of this dynamic interaction is the capacity of the individual for the maintenance of health and recovery from disease**—This self-regulatory capacity can be rephrased as the maintenance of homeostasis. The endocannabinoid system’s capacity to maintain homeostasis has been cited many times in this review, and dozens of additional citations can be found in the exhaustive review by Pacher et al.⁵⁰

The endocannabinoid literature rarely mentions allostasis, a process by which homeostasis adapts to environmental stress. However, it appears in osteopathic medical literature and may become costly in the scenario of chronic stress (“allostatic load”).³⁷ Many studies cited in the present review, especially concerning HPA axis activation and the immune response, indicate that the endocannabinoid system promotes allostasis as well as homeostasis.

3. **Many forces, both intrinsic and extrinsic to the person, can challenge this inherent capacity and contribute to the onset of illness**—Correspondingly, the endocannabinoid system is challenged by intrinsic forces (changes in its structure and genetic expression) and extrinsic forces (changes in its function by unhealthy lifestyles). A corollary to this tenet is the principle that structure and function are interrelated at all levels. Because CB₁ and CB₂ express different molecular structures, they exert different molecular functions.
4. **The musculoskeletal system significantly influences the individual’s ability to restore this inherent capacity and therefore to resist disease processes**—The endocannabinoid system is expressed by the musculoskeletal system.^{10,70} Harnessing it has broad therapeutic potential for treating degenerative and inflammatory conditions of the musculoskeletal system. The fact that insulin resistance resides in skeletal muscles also implicates the endocannabinoid system in its relationship to cardiometabolic risk.⁷⁰

Reciprocal Interactions

A focus on somatic dysfunction, formerly referred to as the “osteopathic lesion,” dates to the founding of osteopathic medicine. Somatic dysfunction is defined as “impaired or altered function of related components of the somatic system:

skeletal, arthroal, and myofascial structures and related vascular, lymphatic, and neural elements.”³⁷ A new model hypothesizing reciprocal interactions between somatic dysfunctions and the endocannabinoid system is presented in the following paragraphs.

In 1910, Still⁹¹ wrote that somatic dysfunction in peripheral tissues “produce[s] pressure and obstruct[s] the normal discharge of nerve and blood supply. Sometimes we find them squeezed so closely as to produce adhesive inflammation.”

The inflammatory basis of somatic dysfunction was demonstrated experimentally by Burns 100 years ago and was subsequently confirmed in humans by Denslow.^{37,92,93} Inflammation arises from three sources: (1) the release of inflammatory mediators by injured tissue, (2) cytokines released by leukocytes that migrate into the area, and (3) inflammatory neuropeptides (substance P and calcitonin gene-related peptide) released from the peripheral terminals of nociceptors.³⁷ All three sources are diminished by the endocannabinoid system, as discussed previously^{36,51,52,60} and as illustrated in *Figure 2*. However, the endocannabinoid system requires the presence of CB₁ in the peripheral terminal of the nociceptor because CB₁ receptors are synthesized in the dorsal root ganglion of nociceptors and are carried by axoplasmic flow to peripheral sites.⁹⁴ By obstructing axoplasmic flow and cellular trafficking of CB₁, the pathophysiology of somatic dysfunction perpetuates itself.

Still² further alluded to axoplasmic flow and attributed the cause of dysfunction to “partial or complete failure of the nerves to properly conduct the fluids of life.” Korr⁹⁵ demonstrated mechanical derangement of axoplasmic flow in rabbits and noted the following:

“Deformations of nerves and roots, such as compression, stretching, angulation, and torsion, that are known to occur all too commonly in the human being [...] are subject to manipulative amelioration and correction.

A rat study demonstrated that a suture loop ligated around the sciatic nerve caused damming of CB₁ proximal to the suture loop (*Figure 2*).⁹⁴ The suture loop may be analogous to myofascial barriers that restrict axoplasmic flow, such as in piriformis contracture, carpal tunnel syndrome, or thoracic outlet restriction. Osteopathic physicians frequently use OMT to treat nerves restricted by mechanical compression^{96,97} and conceivably restore the axoplasmic transport of CB₁.

Central neural mechanisms also perpetuate somatic dysfunction. Still⁹¹ presciently focused on the dorsal horn, stating “the lesion is a sclerosis of the posterior root-zones of the spinal cord.” Denslow described the “facilitated segment” as a sustained neural reflex with motor and autonomic components, whose sensory element was proprioceptive⁹² or nociceptive.⁹³

Willard³⁷ updated and extended the nociceptive model by describing segmental facilitation as a form of central sensitization

driven by excessive glutamate release. The endocannabinoid system again comes into play here by reducing central sensitization, as previously discussed,³⁶ and by dampening sympathetically mediated pain⁵⁰—thereby thwarting the primary “organizers” of somatic dysfunction.⁹²

Chiropractic researchers⁹⁸ implicated glutamate release from nociceptors as the source of long-term potentiation in spinal cord neurons. They noted that long-term potentiation can be reversed by long-term depression and that spinal manipulation imparts long-term depression by an uncertain mechanism.⁹⁸ However, these researchers⁹⁸ did not mention that the endocannabinoid system induces long-term depression, which is caused by a sustained decrease in glutamate release from presynaptic cells.⁴⁰ It has been proposed that high levels of CB₁ expressed in the dorsolateral funiculus of the spinal cord are positioned to influence viscerosomatic reflexes as well.³⁶

Central sensitization is analogous to the upregulation of acetylcholine (ACh) transmission at the motor endplate (ie, the neuromuscular junction), which may be the pathologic process underlying myofascial trigger points.⁸ As my colleague David G. Simmons, MD, and I previously hypothesized,⁸ CB₁ in motor end plates dampen ACh release and perhaps play a role in preventing or treating myofascial trigger points.⁸ Our hypothesis has been supported by two new animal studies^{99,100} showing that CB₁ activation in motor end plates dampens ACh release.

It is important to note that cannabinoids suppress pain responses rather than all somatosensory input because cannabinoids scarcely alter nonnociceptive neurons in the spinal cord and thalamus.³⁶ To wit, the endocannabinoid system inhibits persistent nociception (ie, inflammatory pain, neurogenic pain, chronic pain) more efficiently than acutely evoked nociception. This difference may explain the anecdotal observation that cannabis provides little relief at the dentist’s office.¹³

Beginning with William Garner Sutherland, DO, in 1899, many researchers have made hypotheses regarding the primary respiratory mechanism, known to osteopathic physicians and other clinicians as the cranial rhythmic impulse (CRI).¹⁰¹ The CRI is an oscillatory phenomenon that remains poorly understood and is somewhat difficult to relate. Acupuncturists face a similar situation when asked to describe “chi.” The CRI is usually attributed to the well-documented oscillatory secretion of cerebrospinal fluid (CSF) by ependymal cells that line the choroid plexus and cerebral ventricles.¹⁰¹ Alternatively, the CRI may represent a palpable harmonic frequency, a summation of several biological oscillations, including CSF pulsations, Traube-Hering waves, cardiac pulse, and diaphragmatic respiration.^{102,103}

Given the impact of the endocannabinoid system on many biological oscillators, it is easy to speculate that the endocannabinoid system modulates the CRI. Human CSF is awash with endocannabinoids.^{48,104} Cells lining the rodent and human ventricular system express CB₁ and endocannabinoid

enzymes,^{23,44,105,106} which modulate the rhythmic production of CSF in rodents,¹⁰⁷ control endocannabinoid levels in rodent CSF,¹⁰⁵ and even provide restraint of suture ossification.⁵⁷

An osteopathic procedure that alters the CRI, known as the compression of the fourth cerebral ventricle (CV-4), may transiently increase hydrostatic pressure in the cerebral ventricular system in humans and cats.^{101,108} Conceivably, the increased hydrostatic pressure could trigger CB₁-constitutive activity.⁴⁸ As described in a previous study,²⁶ the angiotensin receptor is stretched into constitutive activity by hydrostatic pressure in a Flexercell apparatus (Flexcell International Corp, Hillsborough, NC).²⁶ Correspondingly, equiaxial stretching of fibroblasts in an identical apparatus caused a doubling of CB₁ expression.¹⁰ The Flexercell management of fibroblasts has provided an *in vitro* model of osteopathic manipulation.¹⁰⁹ Activation of CB₁ may explain many CV-4 effects, such as relaxation and drowsiness, decreased sleep latency, and decreased sympathetic nerve activity.¹¹⁰

Lastly, it should be noted that enhancing the endocannabinoid system improves cardiovascular circulation.^{50,111} This may be one mechanism by which OMT improves health—“the rule of the artery is supreme.”²

Enhancing the Endocannabinoid System

New research with endocannabinoid enzyme inhibitors provides a proof-of-principle for the concept that enhancing endocannabinoid signaling is a beneficial therapeutic strategy.¹¹² Inhibitors of FAAH, an enzyme that breaks down AEA, and MAGL, an enzyme that breaks down 2-AG, are anxiolytic and antidepressant and block nociception, yet the inhibitors do not impart psychoactive effects characteristic of direct CB₁ agonists such as THC.¹¹²

The remainder of this review focuses on three ways to enhance endocannabinoid function: (1) lifestyle modifications, (2) pharmaceutical approaches, and (3) OMT. An increasing number of conditions have been characterized as “endocannabinoid deficiency syndromes,” including posttraumatic stress disorder, chronic anxiety, migraine, Parkinson syndrome, and irritable bowel syndrome.^{104,113} Fibromyalgia may also involve endocannabinoid deficiency. During a normal menstrual cycle, AEA decreases during the luteal phase (circa day 21) as a result of the progesterone-induced upregulation of FAAH.¹¹⁴

In a study of healthy women with normal menstrual cycles, the luteal phase corresponded with hypersensitivity to algometer-induced pressure at fibromyalgia tender points. Several subjects “changed” fibromyalgia diagnosis during the course of a menstrual cycle, fulfilling the tender point criterion—defined as tenderness elicited by 4 kg of pressure at 11 of 18 pressure points—during the AEA-deficient luteal phase or menstrual phase, but never during the AEA-rich follicular phase.¹¹⁴

Studies suggest endocannabinoid deficiency may be rectified by lifestyle modifications, including exercise, stress reduc-

tion, dietary supplements, and drug and alcohol restraint. Exercising on a treadmill or a stationary bike increased AEA levels circulating in the bloodstream.^{67,115} Chronic stress downregulated CB₁ expression in rodents,¹¹⁶ so stress-reduction programs may offer a potential enhancement of the endocannabinoid system.

Dietary inclusion of fish oils with DHA (docosahexaenoate 22:6 ω -3) and other polyunsaturated fatty acids increased AEA and 2-AG levels in the brain.^{117,118} Oral administration of *Lactobacillus* upregulated CB₂ in intestinal epithelial cells and relieved irritable bowel syndrome.¹¹⁹ Acute ethanol ingestion decreased AEA and 2-AG in most regions of the brain,¹²⁰ and chronic ethanol abuse downregulated CB₁ expression.¹²¹

A study of isopropyl dodecylfluorophosphonate, a homolog of organophosphate pesticides, showed that it inhibited both FAAH and MAGL. The inhibition caused 10-fold elevations in AEA and 2-AG in mice, leading to cannabinimetic behavioral effects.¹²² However, when incautious adolescents sprayed cannabis with organophosphate pesticides, the adulteration did not enhance cannabinimetic effects. Instead, it overwhelmed the patients with cholinergic adverse effects.¹²³

Preclinical studies (animal models and human *in vitro* assays) indicate that indomethacin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the endocannabinoid catabolic enzymes COX2 and FAAH,¹²⁴ so NSAIDs prolong the activity of 2-AG and AEA. In animal models, coadministration of NSAIDs with endocannabinoids had a synergistic effect.¹²⁵ This may explain why NSAIDs sometimes cause sedation and other unexpected psychotropic effects in patients. Acetaminophen is deacetylated and conjugated with arachidonic acid into *N*-arachidonoylphenolamine, a compound that activates CB₁.^{126,127}

Dexamethasone potently upregulates CB₁ in rodents.¹²⁸ The tricyclic antidepressant desipramine increases CB₁ densities in the brain of rodents¹²⁹ while fluoxetine decreases CB₁ expression in rodents.¹³⁰ Diazepam and endocannabinoids produce synergistic anxiolytic effects in mice, leading researchers to propose that enhancement of endocannabinoid function increases the effectiveness of diazepam.¹³¹ Valproate sodium, an anticonvulsant and mood-stabilizing drug, upregulates CB₁ in rodents—a newly discovered mechanism of action.¹³²

Cannabidiol and THC may widen their own therapeutic windows by increasing AEA levels.^{61,133-135} Low, subtherapeutic doses of THC markedly potentiate the antinociception imparted by endogenous cannabinoids.⁶¹ Surprisingly, THC upregulates CB₁ expression when administered acutely.¹³⁶ It may also cause post-translational modifications in CB₁ that stabilize the receptor in a constitutively active conformation. Hypothetically, CB₁ may remain constitutively active long after THC has been metabolized and excreted.²² Similar adaptations arise in μ -receptors after chronic exposure to plant opiates.¹³⁷

This discussion brings us back to the medicinal uses of cannabis. Oral administration of cannabis shares drawbacks with dronabinol capsules—erratic gut bioavailability, poor dose titration, and THC taken by mouth is converted to an 11-hydroxy-THC metabolite with two to five times more psychoactivity.¹³⁸ Oral administration is difficult in patients who are nauseated or vomiting. Smoking cannabis is a health hazard due to polyaromatic hydrocarbons formed during combustion. Vaporization of cannabis provides an alternative to smoking, recently described in the *New England Journal of Medicine*.¹⁷ Because THC vaporizes at a temperature below the ignition point of combustible plant material, few polyaromatic hydrocarbons appear in the vapor.

Cannabis, of course, is more than THC. Other ingredients provide additional benefits and mitigate the adverse effects of THC.⁷⁹ For this reason, many patients prefer cannabis to dronabinol. Cannabidiol, for example, reduces dysphoria and depersonalization provoked by THC while contributing its own anxiolytic, antipsychotic, analgesic, antiemetic, anticarcinogenic, antioxidant, and neuroprotective effects.¹³⁹ Indeed, the risk posed by new high-potency cannabis may be the lack of cannabidiol in current strains of cannabis rather than the increase in THC levels.¹⁴⁰ Median THC levels have only increased five fold since the 1970s, analogous to the five fold difference in caffeine between green tea and percolated coffee.¹⁴⁰

Sativex, a botanical extract standardized to contain a 50:50 mix of THC and cannabidiol, has been approved for phase 3 trials in the United States. It is currently licensed in Europe and Canada for multiple sclerosis, neuropathic pain, and cancer-related pain. The product is sprayed under the tongue, where it is absorbed into the bloodstream. Extension studies have shown that Sativex retains efficacy for at least 4 years, without drug tolerance or dose escalation and with no evidence of dependency or abuse.¹⁴¹

Many patients have reported that OMT induces anxiolysis, eases suffering, increases sense of well-being, and even induces euphoria—psychotropic changes that can be described as cannabinimimetic.⁵ Osteopathic manipulative treatment may induce such effects by boosting endocannabinoid levels.

A blinded, randomized controlled trial of 31 healthy subjects measured AEA levels pre- and post-OMT.⁵ The OMT intervention consisted of myofascial release and muscle energy and thrust techniques. The control intervention consisted of a sham cranial method. In subjects receiving OMT, serum levels of AEA obtained after OMT more than doubled the pre-OMT levels. No change was seen in control subjects.⁵ However, the doubling of AEA was not statistically significant ($P=.139$) because of a large degree of response variability.

A smaller OMT trial reported little change in AEA levels pre- and post-OMT but showed significant post-OMT augmentation of *N*-palmitoylethanolamine.⁹ In rodent studies, *N*-palmitoylethanolamine increased the antinociceptive effects of AEA via an “entourage effect.”^{30,142}

Speculatively, OMT may work “skin deep,” causing endocannabinoid release from keratinocytes. Epidermal endocannabinoids activate CB₁ expressed on the peripheral terminals of nociceptors and provide the “first line of defense against pain.”⁶⁰ A similar mechanism, epidermal “pounding of the pavement” by distance runners, was proposed as the source of endocannabinoid-induced “runner’s high.”¹¹⁵

Conclusion

The endocannabinoid system has emerged as an important regulator of psychoneuroimmunologic function. Modulating CB₁, CB₂, and endocannabinoids represent new approaches for treating a variety of functional disorders, such as supplementing receptors with exogenous agonists (eg, dronabinol).

Strategies that augment endocannabinoids offer the advantage of enhancing endocannabinoid function at localized sites of pathology already targeted by homeostatic mechanisms. For example, chronic pain syndromes lead to elevated expression of CB₁ in two localized sites: the PAG and the dorsal horn.^{18,36} In rodent studies, augmenting endocannabinoids at these receptors relieved nociception at doses that did not elicit supratentorial effects.¹⁴³

This strategy echoes the osteopathic concept that the body possesses self-regulatory mechanisms that are self-healing in nature. Neuroscience investigations regarding the endocannabinoid system may continue to reveal many of the mind-body underpinnings of osteopathic medicine.

Acknowledgments

I dedicate this paper to the memory of J. Michael Walker, PhD, who reviewed the manuscript before submission. I thank Patricia Pruitt, DVM, for manuscript review and discussion. Key quotes by Andrew T. Still, MD, DO, were confirmed by Steve Paulus, DO, at the A.T. Still Library (www.interlinea.org) based in Soquel, Calif.

References

- Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail [review]. *Br J Pharmacol*. 2006;147(suppl 1):S153-S162. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16402099>. Accessed September 10, 2008.
- Still AT. *Autobiography of Andrew T. Still*. Kirksville, Mo: AT Still; 1897.
- Goldstein M. Introduction to the symposium on endorphins and neurotransmitters. *J Am Osteopath Assoc*. 1984;84:96-97.
- McPartland JM. The serendipity of health and the botany of desire. In: *UNITEC Research and Development Report 2001-2002*. Auckland, NZ: UNITEC Press; 2002:42-43.
- McPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE. Cannabimimetic effects of osteopathic manipulative treatment. *J Am Osteopath Assoc*. 2005;105:283-291. Available at: <http://www.jaoa.org/cgi/content/full/105/6/283>. Accessed September 10, 2008.
- Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, et al. Involvement of the cannabinimimetic compound, *N*-palmitoylethanolamine, in inflammatory and neuropathic conditions: review of the available preclinical data, and first human studies. *Neuropharmacology*. 2005;48:1154-1163.

7. Stefano GB, Salamon EJ IV. Nitric oxide and anandamide in OMT research [letter]. *J Am Osteopath Assoc*. 2006;106:588-589. Available at: <http://www.jaoa.org/cgi/content/full/106/10/588>. Accessed September 10, 2008.
8. McPartland JM, Simons DG. Myofascial trigger points: translating molecular theory into manual therapy. *J Manual Manipulative Ther*. 2006;14:232-239.
9. Degenhardt BF, Darmani NA, Johnson JC, Towns LC, Rhodes DC, Trinh C, et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. *J Am Osteopath Assoc*. 2007;107:387-400. Available at: <http://www.jaoa.org/cgi/content/full/107/9/387>. Accessed September 10, 2008.
10. McPartland JM. Expression of the endocannabinoid system in fibroblasts and myofascial tissues. *J Bodywork Movement Ther*. 2008;12:169-182.
11. Rogers FJ, D'Alonzo GE Jr, Glover JC, Korr IM, Osborn GG, Patterson MM, et al. Proposed tenets of osteopathic medicine and principles for patient care [New & Noteworthy]. *J Am Osteopath Assoc*. 2002;102:63-65. Available at: <http://www.jaoa.org/cgi/reprint/102/2/63>. Accessed September 8, 2008.
12. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, ed. *Cannabinoids as Therapeutic Agents*. Boca Raton, Fla: CRC Press; 1986:1-19.
13. Robson P. Human studies of cannabinoids and medicinal cannabis. *Handb Exp Pharmacol*. 2005;719-756.
14. Wood GB. *The Dispensatory of the United States of America*. 10th ed. Philadelphia, Pa: Lippincott and Grambo; 1854:1480.
15. Osler W, McCrae T. *The Principles and Practice of Medicine*. New York, NY: Appleton and Company; 1915.
16. Fishbein M. Federal regulation of medicinal use of cannabis. *JAMA*. 1937;108:1543-1544.
17. Okie S. Medical marijuana and the Supreme Court. *N Engl J Med*. 2005;353:648-651. Available at: <http://content.nejm.org/cgi/content/full/353/7/648>. Accessed September 8, 2008.
18. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids [review]. *AAPS J*. 2005;7:E625-E654. Available at: <http://www.aapsj.org/view.asp?art=aapsj070364>. Accessed September 8, 2008.
19. Marinol. In: *Physicians' Desk Reference*. 62nd ed. Montvale, NJ: Thomson Healthcare; 2007:3271-3273.
20. Cesamet (nabilone) fact sheet. Valeant Pharmaceuticals International Web site. Available at: http://www.valeant.com/fileRepository/media/Cesamet_Fact_Sheet.pdf. Accessed September 8, 2008.
21. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors [review]. *Pharmacol Rev*. 2002;54:161-202. Available at: <http://pharm.rev.aspetjournals.org/cgi/content/full/54/2/161>. Accessed September 10, 2008.
22. McPartland JM, Guy G. The evolution of Cannabis and coevolution with the cannabinoid receptor—a hypothesis. In: Guy GV, Whittle BA, Robson PJ, eds. *The Medicinal Uses of Cannabis and Cannabinoids*. London, UK: Pharmaceutical Press; 2004:71-102.
23. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience*. 1997;77:299-318.
24. Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of delta-9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. *Eur J Pharmacol*. 2003;459:139-150.
25. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnesic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. *Neuropsychopharmacology*. 2008;33:2505-2516.
26. Zou Y, Takano H, Akazawa H, Nagai T, Mizukami M, Komuro I. Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy. *Endocr J*. 2002;49:1-13.
27. McPartland JM, Glass M, Matias I, Norris RW, Kilpatrick CW. A shifted repertoire of endocannabinoid genes in the zebrafish (*Danio rerio*). *Mol Genet Genomics*. 2007;277:555-570.
28. McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. *Gene*. 2006;370:64-74.
29. McPartland JM, Norris RW, Kilpatrick CW. Tempo and mode in endocannabinoid system evolution. *J Mol Evol*. 2007;65:267-276.
30. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. *Eur J Pharmacol*. 1998;359:1-18.
31. Straiker A, Mackie K. Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years. *AAPS J*. 2006;8:E272-E276. Available at: <http://www.aapsj.org/view.asp?art=aapsj080231>. Accessed September 11, 2008.
32. Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. *J Pharmacol Sci*. 2004;96:367-375. Available at: http://www.jstage.jst.go.jp/article/jphs/96/4/367/_pdf. Accessed September 11, 2008.
33. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences. *Br J Pharmacol*. 2007;152:583-589.
34. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol*. 2007;14:1347-1356.
35. Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, et al. Hemopressin is an inverse agonist of CB₁ cannabinoid receptors. *Proc Natl Acad Sci USA*. 2007;104:20588-20593. Available at: <http://www.pnas.org/content/104/51/20588>. Accessed September 11, 2008.
36. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. In: Pertwee RG, ed. *Cannabinoids (Handbook of Experimental Pharmacology)*. Berlin, Germany: Springer-Verlag; 2005:509-554.
37. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In: Ward RC, ed. *Foundations for Osteopathic Medicine*. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:137-156.
38. Viveros MP, Marco EM, Llorente R, López-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses [review]. *Neural Plast*. 2007;2007:52908. Available at: <http://www.hindawi.com/GetArticle.aspx?doi=10.1155/2007/52908>. Accessed September 11, 2008.
39. Morisset V, Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. *J Neurophysiol*. 2001;86:40-48. Available at: <http://jn.physiology.org/cgi/content/full/86/1/40>. Accessed September 11, 2008.
40. Gerdeman GL, Lovinger DM. Emerging roles for endocannabinoids in long-term synaptic plasticity. *Br J Pharmacol*. 2003;140:781-789. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=14504143>. Accessed September 11, 2008.
41. Park B, McPartland JM, Glass M. Cannabis, cannabinoids and reproduction. *Prostaglandins Leukot Essent Fatty Acids*. 2004;70:189-197.
42. Harkany T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. *Trends Pharmacol Sci*. 2007;28:83-92.
43. Berghuis P, Rajniecek AM, Morozov YM, Ross RA, Mulder J, Urbán GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. *Science*. 2007;316:1212-1216.
44. Curtis MA, Faull RL, Glass M. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. *J Chem Neuroanat*. 2006;31:210-215.
45. Aguado T, Romero E, Monroy K, Palazuelos J, Sendtner M, Marsicano G, et al. The CB₁ cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. *J Biol Chem*. 2007;282:23892-23898.

Available at: <http://www.jbc.org/cgi/content/full/282/33/23892>. Accessed September 12, 2008.

46. Jealous J. Personal Communication. Cited by: McPartland JM, Skinner E. The biodynamic model of osteopathy in the cranial field. *Explore (NY)*. 2005;1:21-32.

47. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. *Lancet Neurol*. 2003;2:291-298.

48. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology*. 2004;29:2108-2114.

49. Zuairi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug [review] [published online ahead of print April 3, 2006]. *Braz J Med Biol Res*. 2006;39:421-429. Available at: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400001&lng=en&nrm=iso&tlng=en. Accessed September 12, 2008.

50. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy [review]. *Pharmacol Rev*. 2006;58:389-462. Available at: <http://pharmrev.aspetjournals.org/cgi/content/full/58/3/389>. Accessed September 12, 2008.

51. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol*. 2005;5:400-411.

52. Ashton JC. Cannabinoids for the treatment of inflammation. *Curr Opin Investig Drugs*. 2007;8:373-384.

53. Emboden WA. Adaptogens: a new formula for health? *Osteopath Physician*. August 1976;43(8):68-70,73.

54. Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, et al. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects [published online ahead of print March 17, 2006]. *J Biol Chem*. 2006;281:14192-14206. Available at: <http://www.jbc.org/cgi/content/full/281/20/14192>. Accessed September 12, 2008.

55. Schuelert N, McDougall JJ. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. *Arthritis Rheum*. 2008;58:145-153.

56. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehne J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. *Science*. 2007;316:1494-1497.

57. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB₂, regulates bone mass. *Proc Natl Acad Sci USA*. 2006;103:696-701. Available at: <http://www.pnas.org/content/103/3/696>. Accessed September 12, 2008.

58. Guzmán M. Cannabinoids: potential anticancer agents. *Nat Rev Cancer*. 2003;3:745-755.

59. Jordà MA, Lowenberg B, Delwel R. The peripheral cannabinoid receptor CB₂, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. *Blood*. 2003;101:1336-1343. Available at: <http://bloodjournal.hematologylibrary.org/cgi/content/full/101/4/1336>. Accessed September 12, 2008.

60. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat Neurosci*. 2007;10:870-879. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17558404>. Accessed September 12, 2008.

61. Suplita RL II, Eisenstein SA, Neely MH, Moise AM, Hohmann AG. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. *Neuropharmacology*. 2007;54:161-171.

62. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB₂ cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc Natl Acad Sci USA*. 2005;102:3093-3098. Available at: <http://www.pnas.org/content/102/8/3093>. Accessed September 12, 2008.

63. Lafenêtre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB₁ receptors may modulate fear extinction. *Pharmacol Res*. 2007;56:367-381.

64. Phan KL, Angstadt M, Golden J, Onyewuanyi I, Popovska A, de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. *J Neurosci*. 2008;28:2313-2319. Available at: <http://www.jneurosci.org/cgi/content/full/28/10/2313>. Accessed September 12, 2008.

65. Manning BH, Martin WJ, Meng ID. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. *Neuroscience*. 2003;120:1157-1170.

66. Weil AT, Zinberg NE, Nelsen JM. Clinical and psychological effects of marihuana in man. *Science*. 1968;162:1234-1242.

67. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. *Neuroreport*. 2003;14:2209-2211.

68. Blechschmidt E. *Beginnings of Human Life*. Berlin, Germany: Springer-Verlag; 1977.

69. Fride E. The endocannabinoid-CB(1) receptor system in pre- and post-natal life. *Eur J Pharmacol*. 2004;500:289-297.

70. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. *Trends Endocrinol Metab*. 2007;18:27-37.

71. FDA Briefing Document: New Drug Application 21-888. *Zimulti (rimonabant) Tablets, 20 mg*. Washington, DC: Food and Drug Administration; 2007. Available at: <http://www.fda.gov/ohrms/dockets/AC07/briefing/2007-4306b1fda-backgrounder.pdf>. Accessed September 12, 2008.

72. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet*. 2007;370:1706-1713.

73. Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes? *Lancet*. 2006;368:1632-1634.

74. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB₁ cannabinoid receptors in emotional behaviour. *Psychopharmacology (Berl)*. 2002;159:379-387.

75. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB₁ receptor knockout mice. *Proc Natl Acad Sci U S A*. 1999;96:5780-5785. Available at: <http://www.pnas.org/content/96/10/5780>. Accessed September 12, 2008.

76. Steffens M, Szabo B, Klar M, Rominger A, Zentner J, Feuerstein TJ. Modulation of electrically evoked acetylcholine release through cannabinoid CB₁ receptors: evidence for an endocannabinoid tone in the human neocortex. *Neuroscience*. 2003;120:455-465.

77. Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merce R, et al. Chronic 5-HT₆ receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats [published correction appears in *Br J Pharmacol*. 2007;151:564]. *Br J Pharmacol*. 2006;148:973-983. <http://www.nature.com/bjpp/journal/v148/n7/full/0706807a.html>. Accessed September 12, 2008.

78. Qiu J. Traditional medicine: a culture in the balance. *Nature*. 2007;448:126-128.

79. McPartland JM, Pruitt PL. Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana [review]. *Altern Ther Health Med*. 1999;5:57-62.

80. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selective non-selective selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov*. 2004;3:353-359.

81. Holley SA, Takeda H. Catching a wave: the oscillator and wavefront that create the zebrafish somite. *Semin Cell Dev Biol*. 2002;13:481-488.

82. Begbie J, Doherty P, Graham A. Cannabinoid receptor, CB₁, expression follows neuronal differentiation in the early chick embryo. *J Anat*. 2004;205:213-218. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15379926>. Accessed September 12, 2008.

83. Williams EJ, Walsh FS, Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. *J Cell*

- Biol.* 2003;160:481-486. Available at: <http://www.jcb.org/cgi/content/full/160/4/481>. Accessed September 12, 2008.
84. Galarreta M, Erdélyi F, Szabó G, Hestrin S. Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors. *J Neurosci.* 2004;24:9770-9778. Available at: <http://www.jneurosci.org/cgi/content/full/24/44/9770>. Accessed September 12, 2008.
85. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsáki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function [published online ahead of print November 19, 2006]. *Nat Neurosci.* 2006;9:1526-1533.
86. Crystal JD, Maxwell KW, Hohmann AG. Cannabinoid modulation of sensitivity to time. *Behav Brain Res.* 2003;144:57-66.
87. O'Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, et al. Marijuana alters the human cerebellar clock. *Neuroreport.* 2003;14:1145-1151.
88. Wittmann G, Deli L, Kalló I, Hrabovszky E, Watanabe M, Liposits Z, et al. Distribution of type 1 cannabinoid receptor (CB₁)-immunoreactive axons in the mouse hypothalamus. *J Comp Neurol.* 2007;503:270-279.
89. Perron RR, Tyson RL, Sutherland GR. Delta9-tetrahydrocannabinol increases brain temperature and inverts circadian rhythms. *Neuroreport.* 2001;12:3791-3794.
90. Steardo L, Cottone P, Sabino V, Monteleone P, Arcidiacono D, Valenti M, et al. Evidence for a regulatory role of endocannabinoid system in the rat pineal gland activity [abstract]. In: *2004 Symposium on the Cannabinoids*. International Cannabinoid Research Society; 2004:76.
91. Still AT. *Osteopathy: Research and Practice*. Kirksville, Mo: AT Still; 1910.
92. Korr IM. The spinal cord as organizer of disease processes: some preliminary perspectives. *J Am Osteopath Assoc.* 1976;76:35-45.
93. Van Buskirk RL. Nociceptive reflexes and the somatic dysfunction: a model. *J Am Osteopath Assoc.* 1990;90:792-794,797-809. Available at: <http://www.jaoa.org/cgi/reprint/90/9/792>. Accessed September 12, 2008.
94. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. *Neuroscience.* 1999;92:1171-1175.
95. Korr IM, Appeltauer GSL. Trophic functions of nerves. In: Beal MC, ed. *1994 Yearbook: Louisa Burns Memorial*. Indianapolis, Ind: American Academy of Osteopathy; 1994:52-60.
96. Sucher BM. Palpatory diagnosis and manipulative management of carpal tunnel syndrome: part 2. 'Double crush' and thoracic outlet syndrome. *J Am Osteopath Assoc.* 1995;95:471-479.
97. Andrews MAW, Andrye KA, Valentine KL, Petrizzo AM, Cohen A. The ameliorative effects of osteopathic manipulative therapy (OMT) in the treatment of sciatic nerve compression. *J Osteopath Med.* 2003;6:39.
98. Boal RW, Gillette RG. Central neuronal plasticity, low back pain and spinal manipulative therapy. *J Manipulative Physiol Ther.* 2004;27:314-326.
99. Sanchez-Pastor E, Trujillo X, Huerta M, Andrade F. Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction. *J Pharmacol Exp Ther.* 2007;321:439-445. Available at: <http://jpet.aspetjournals.org/cgi/content/full/321/2/439>. Accessed September 12, 2008.
100. Newman Z, Malik P, Wu TY, Ochoa C, Watsa N, Lindgren C. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. *Eur J Neurosci.* 2007;25:1619-1630. Available at: <http://www3.interscience.wiley.com/cgi-bin/fulltext/118542570/HTMLSTART>. Accessed September 12, 2008.
101. Sutherland AS, Wales A, eds. *Contributions of Thought: The Collected Writings of William Garner Sutherland*. Kansas City, Mo: Sutherland Cranial Teaching Foundation; 1967.
102. McPartland JM, Mein EA. Entrainment and the cranial rhythmic impulse [review]. *Altern Ther Health Med.* 1997;3:40-45.
103. Nelson KE, Sergueef N, Glonek T. Recording the rate of the cranial rhythmic impulse. *J Am Osteopath Assoc.* 2006;106:337-341. Available at: <http://www.jaoa.org/cgi/content/full/106/6/337>. Accessed September 12, 2008.
104. Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. *Neuropsychopharmacology.* 2007;32:1384-1390.
105. Egertova M, Michael GJ, Cravatt BF, Elphick MR. Fatty acid amide hydrolyase in brain ventricular epithelium: mutually exclusive patterns of expression in mouse and rat. *J Chem Neuroanat.* 2004;28:171-181.
106. Ashton JC, Appleton I, Darlington CL, Smith PF. Cannabinoid CB₁ receptor protein expression in the rat choroid plexus: a possible involvement of cannabinoids in the regulation of cerebrospinal fluid. *Neurosci Lett.* 2004;364:40-42.
107. Mancall AC, DiGregorio GJ, Brill CB, Ruch E. The effect of delta-9-tetrahydrocannabinol on rat cerebrospinal fluid. *Arch Neurol.* 1985;42:1069-1071.
108. Adams T, Heisey RS, Smith MC, Briner BJ. Parietal bone mobility in the anesthetized cat. *J Am Osteopath Assoc.* 1992;92:599-600,603-610,615-622. Available at: <http://www.jaoa.org/cgi/reprint/92/5/599>. Accessed September 12, 2008.
109. Eagan TS, Meltzer KR, Standley PR. Importance of strain direction in regulating human fibroblast proliferation and cytokine secretion: a useful in vitro model for soft tissue injury and manual medicine treatments. *J Manipulative Physiol Ther.* 2007;30:584-592.
110. Cutler MJ, Holland BS, Stupski BA, Gamber RG, Smith ML. Cranial manipulation can alter sleep latency and sympathetic nerve activity in humans: a pilot study. *J Altern Complement Med.* 2005;11:103-108.
111. Hillard CJ, Ho WS, Thompson J, Gauthier KM, Wheelock CE, Huang H, et al. Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. *Br J Pharmacol.* 2007;152:691-698.
112. Ross RA. Allosterism and cannabinoid CB₁ receptors: the shape of things to come [review]. *Trends Pharmacol Sci.* 2007;28:567-572.
113. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions [review]? *Neuro Endocrinol Lett.* 2004;25:31-39.
114. Dunnett AJ, Roy D, Stewart A, McPartland JM. The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase. *J Bodywork Movement Ther.* 2007;11:99-105.
115. Dietrich A, McDaniel WF. Endocannabinoids and exercise [review]. *Br J Sports Med.* 2004;38:536-541. Available at: <http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1724924&blobtype=pdf>. Accessed September 12, 2008.
116. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. *Neuropsychopharmacology.* 2005;30:508-515.
117. Watanabe S, Doshi M, Hamazaki T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. *Prostaglandins Leukot Essent Fatty Acids.* 2003;69:51-59.
118. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acyl ethanolamines in piglets. *Proc Natl Acad Sci U S A.* 2001;98:6402-6406. Available at: <http://www.pnas.org/content/98/11/6402>. Accessed September 12, 2008.
119. Rousseau C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. *Nat Med.* 2007;13:35-37.
120. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. *Brain Res.* 2002;954:73-81.
121. Ortiz S, Oliva JM, Pérez-Rial S, Palomo T, Manzanares J. Chronic ethanol consumption regulates cannabinoid CB₁ receptor gene expression in selected regions of rat brain. *Alcohol Alcohol.* 2004;39:88-92. Available at: <http://alcalc.oxfordjournals.org/cgi/content/full/39/2/88>. Accessed September 12, 2008.

(continued)

122. Nomura DK, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, et al. Activation of the endocannabinoid system by organophosphorus nerve agents. *Nat Chem Biol*. 2008;4:373-378.
123. McPartland JM, Blanchon D, Musty RE. Cannabimimetic effects modulated by cholinergic compounds. *Addict Biol*. 2008;13:411-415.
124. Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. *Trends Pharmacol Sci*. 2004;25:59-61.
125. Guindon J, LoVerme J, De Léan A, Piomelli D, Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? *Eur J Pharmacol*. 2006;550:68-77.
126. Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. *J Biol Chem*. 2005;280:31405-31412. Available at: <http://www.jbc.org/cgi/content/full/280/36/31405>. Accessed September 12, 2008.
127. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia [published online ahead of print May 15, 2008]. *Pain*. 2008;139:190-200.
128. Wang S, Lim G, Mao J, Sung B, Yang L, Mao J. Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. *Pain*. 2007;131:96-105.
129. Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. *Neuropsychopharmacology*. 2006;31:2591-2599.
130. Oliva JM, Urigüen L, Pérez-Rial S, Manzanares J. Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. *Neuropharmacology*. 2005;49:618-626.
131. Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, Khani A, et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. *Pharmacol Biochem Behav*. 2008;89:64-75.
132. Goffin K, Bormans G, Casteels C, Bosier B, Lambert DM, Grachev ID, et al. An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. *Neuropharmacology*. 2008;54:1103-1106.
133. Burstein SH, Hunter SA. Stimulation of anandamide biosynthesis in N-18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). *Biochem Pharmacol*. 1995;49:855-858.
134. Rakhshan F, Day TA, Blakely RD, Barker EL. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. *J Pharmacol Exp Ther*. 2000;292:960-967. Available at: <http://jpet.aspetjournals.org/cgi/content/full/292/3/960>. Accessed September 12, 2008.
135. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*. 2001;134:845-852. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=11606325>. Accessed September 12, 2008.
136. Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. *J Pharmacol Exp Ther*. 2001;297:121-127. Available at: <http://jpet.aspetjournals.org/cgi/content/full/297/1/121>. Accessed September 12, 2008.
137. Chavkin C, McLaughlin JP, Celver JP. Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. *Mol Pharmacol*. 2001;60:20-25. Available at: <http://molpharm.aspetjournals.org/cgi/content/full/60/1/20>. Accessed September 12, 2008.
138. McPartland JM, Pruitt PL. Medical marijuana and its use by the immunocompromised. *Altern Ther Health Med*. 1997;3:39-45.
139. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses*. 2006;66:234-246.
140. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. *J Forensic Sci*. 2008;53:90-94.
141. Russo EB. The solution to the medicinal cannabis problem. In: Schatman ME, ed. *Ethical Issues in Chronic Pain Management*. New York, NY: Informa Healthcare USA; 2007:165-194.
142. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors [published ahead of print July 2, 2008]. *Pain*.
143. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. *J Pharmacol Exp Ther*. 2004;311:441-448. Available at: <http://jpet.aspetjournals.org/cgi/content/full/311/2/441>. Accessed September 12, 2008.
-